• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局限型硬皮病、弥漫型硬皮病和系统性硬化症的生存和死亡率预测因素。

Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality.

机构信息

Department of Internal Medicine, CHU Toulouse, Toulouse, Midi-Pyrénées, France.

INSERM UMR1027, 37 Allées Jules Guesdes, Toulouse, Midi-Pyrénées, France.

出版信息

Arthritis Res Ther. 2021 Dec 7;23(1):295. doi: 10.1186/s13075-021-02672-y.

DOI:10.1186/s13075-021-02672-y
PMID:34876194
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8650544/
Abstract

BACKGROUND

Systemic sclerosis (SSc) is associated with a variability of mortality rates in the literature.

OBJECTIVE

To determine the mortality and its predictors in a long-term follow-up of a bi-centric cohort of SSc patients.

METHODS

A retrospective observational study by systematically analyzing the medical records of patients diagnosed with SSc in Toulouse University Hospital and Ducuing Hospital. Standardized Mortality Ratio (SMR), mortality at 1, 3, 5, 10, and 15 years of disease and causes of death were described. Predictors of mortality using Cox regression were assessed.

RESULTS

Three hundred seventy-five patients were included: 63 with diffuse cutaneous SSc, 279 with limited cutaneous SSc, and 33 with sine scleroderma. The SMR ratio was 1.88 (95% CI 1.46-1.97). The overall survival rates were 97.6% at 1 year, 93.4% at 3 years, 87.1% at 5 years, 77.9% at 10 years, and 61.3% at 15 years. Sixty-nine deaths were recorded. 46.4% were SSc related deaths secondary to interstitial lung disease (ILD) (34.4%), pulmonary hypertension (31.2%), and digestive tract involvement (18.8%). 53.6% were non-related to SSc: cardiovascular disorders (37.8%) and various infections (35.1%) largely distanced those from cancer (13.5%). Four significant independent predictive factors were identified: carbon monoxide diffusing capacity (DLCO) < 70% (HR=3.01; p=0.0053), C-reactive protein (CRP) >5 mg/l (HR=2.13; p=0.0174), cardiac involvement (HR=2.86; p=0.0012), and the fact of being male (HR=3.25; p=0.0004).

CONCLUSION

Long-term data confirmed high mortality of SSc. Male sex, DLCO <70%, cardiac involvement, and CRP> 5mg/l were identified as independent predictors of mortality.

摘要

背景

系统性硬化症(SSc)的文献报道死亡率存在差异。

目的

通过对图卢兹大学医院和 Ducuing 医院的 SSc 患者进行双中心队列的长期随访,确定死亡率及其预测因素。

方法

通过系统分析患者的病历,对在图卢兹大学医院和 Ducuing 医院诊断为 SSc 的患者进行回顾性观察性研究。描述标准化死亡率(SMR)、疾病 1、3、5、10 和 15 年的死亡率和死亡原因。使用 Cox 回归评估死亡率的预测因素。

结果

共纳入 375 例患者:弥漫性皮肤型 SSc 63 例,局限性皮肤型 SSc 279 例,无皮肤型 SSc 33 例。SMR 比值为 1.88(95%CI 1.46-1.97)。1 年总生存率为 97.6%,3 年生存率为 93.4%,5 年生存率为 87.1%,10 年生存率为 77.9%,15 年生存率为 61.3%。记录到 69 例死亡。46.4%与 SSc 相关,死于间质性肺病(ILD)(34.4%)、肺动脉高压(31.2%)和消化道受累(18.8%)。53.6%与 SSc 无关:心血管疾病(37.8%)和各种感染(35.1%)在很大程度上降低了癌症(13.5%)的死亡率。确定了四个有意义的独立预测因素:一氧化碳弥散量(DLCO)<70%(HR=3.01;p=0.0053)、C 反应蛋白(CRP)>5mg/l(HR=2.13;p=0.0174)、心脏受累(HR=2.86;p=0.0012)和男性(HR=3.25;p=0.0004)。

结论

长期数据证实 SSc 死亡率较高。男性、DLCO<70%、心脏受累和 CRP>5mg/l 是死亡率的独立预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/668be0291fe1/13075_2021_2672_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/33d861c7e4fb/13075_2021_2672_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/e1bd82228d30/13075_2021_2672_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/668be0291fe1/13075_2021_2672_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/33d861c7e4fb/13075_2021_2672_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/e1bd82228d30/13075_2021_2672_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/8650544/668be0291fe1/13075_2021_2672_Fig3_HTML.jpg

相似文献

1
Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality.局限型硬皮病、弥漫型硬皮病和系统性硬化症的生存和死亡率预测因素。
Arthritis Res Ther. 2021 Dec 7;23(1):295. doi: 10.1186/s13075-021-02672-y.
2
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.系统性硬化症相关间质性肺病伴或不伴肺动脉高压对生存的影响:德国系统性硬化症网络的一项大型队列研究。
Chest. 2024 Jan;165(1):132-145. doi: 10.1016/j.chest.2023.08.013. Epub 2023 Aug 13.
3
Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.系统性硬化症的间质性肺疾病:来自西班牙硬皮病研究组的数据。
Rheumatol Int. 2018 Mar;38(3):363-374. doi: 10.1007/s00296-017-3916-x. Epub 2018 Jan 10.
4
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.系统性硬化症的生存和预后因素:一项法国多中心队列研究、系统评价和文献荟萃分析的数据。
Arthritis Res Ther. 2019 Apr 3;21(1):86. doi: 10.1186/s13075-019-1867-1.
5
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients.来自意大利未选择的系统性硬化症患者多中心大型队列的生存及预后因素
Rheumatology (Oxford). 2023 Apr 3;62(4):1552-1558. doi: 10.1093/rheumatology/keac512.
6
Determinants of morbidity and mortality of systemic sclerosis in Canada.加拿大系统性硬化症发病率和死亡率的决定因素。
Semin Arthritis Rheum. 2010 Feb;39(4):269-77. doi: 10.1016/j.semarthrit.2008.06.002. Epub 2008 Aug 15.
7
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.硬皮病谱系疾病相关肺动脉高压的生存情况:间质性肺疾病的影响
Arthritis Rheum. 2009 Feb;60(2):569-77. doi: 10.1002/art.24267.
8
Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.C 反应蛋白与系统性硬化症高疾病活动度的相关性:来自加拿大硬皮病研究组的研究结果。
Arthritis Care Res (Hoboken). 2012 Sep;64(9):1405-14. doi: 10.1002/acr.21716.
9
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.合并和不合并间质性肺疾病的系统性硬化症中重度肺动脉高压的患病率及特征
J Rheumatol. 2007 May;34(5):1005-11. Epub 2007 Apr 15.
10
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.系统性硬皮病相关间质性肺疾病肺动脉高压的临床特征和生存。
Chest. 2011 Oct;140(4):1016-1024. doi: 10.1378/chest.10-2473. Epub 2011 Apr 7.

引用本文的文献

1
Safety and long-term efficacy of autologous hematopoietic cell transplantation for patients with systemic sclerosis.自体造血细胞移植治疗系统性硬化症患者的安全性和长期疗效
Front Med (Lausanne). 2025 Jul 14;12:1527779. doi: 10.3389/fmed.2025.1527779. eCollection 2025.
2
Machine Learning Analysis of Electronic Health Records Identifies Interstitial Lung Disease and Predicts Mortality in Patients with Systemic Sclerosis.电子健康记录的机器学习分析可识别间质性肺病并预测系统性硬化症患者的死亡率。
medRxiv. 2025 Jun 4:2025.06.02.25328786. doi: 10.1101/2025.06.02.25328786.
3
Sex Bias in Systemic Sclerosis: from Clinical to Immunological Differences.

本文引用的文献

1
Prediction of organ involvement and survival in systemic sclerosis patients in the first 5 years from diagnosis.系统性硬化症患者诊断后前5年器官受累情况及生存率的预测
J Scleroderma Relat Disord. 2020 Feb;5(1):57-65. doi: 10.1177/2397198319869564. Epub 2019 Sep 6.
2
Assessment of the Accuracy of Using Codes to Identify Systemic Sclerosis.使用编码识别系统性硬化症的准确性评估
Clin Epidemiol. 2020 Dec 8;12:1355-1359. doi: 10.2147/CLEP.S260733. eCollection 2020.
3
Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis.
系统性硬化症中的性别偏见:从临床差异到免疫差异
Clin Rev Allergy Immunol. 2025 May 27;68(1):51. doi: 10.1007/s12016-025-09062-1.
4
Characterization of Circulating Vesicles of Complicated and Uncomplicated Systemic Sclerosis Patients and Their Role in Vascular Dysfunction.复杂型和非复杂型系统性硬化症患者循环囊泡的特征及其在血管功能障碍中的作用
Int J Mol Sci. 2025 Mar 7;26(6):2380. doi: 10.3390/ijms26062380.
5
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis.用于预测局限性皮肤型系统性硬化症中有临床意义的疾病进展的血清I型干扰素评分
Arthritis Rheumatol. 2025 Jul;77(7):929-941. doi: 10.1002/art.43120. Epub 2025 Mar 3.
6
Assessment of Neutrophil-Lymphocyte Ratio and Systemic Immune-Inflammation Index in Systemic Scleroderma Patients with Focus on Cardiopulmonary Manifestations.系统性硬化症患者中性粒细胞与淋巴细胞比值及全身免疫炎症指数的评估:聚焦心肺表现
Curr Health Sci J. 2024 Jul-Sep;50(3):421-427. doi: 10.12865/CHSJ.50.03.09. Epub 2024 Sep 30.
7
Biomarkers in the evaluation of cardiac involvement in systemic sclerosis.生物标志物在系统性硬化症心脏受累评估中的应用
Rheumatol Immunol Res. 2024 Jul 15;5(2):99-106. doi: 10.1515/rir-2024-0013. eCollection 2024 Jun.
8
Trace Element Deficiency in Systemic Sclerosis-Too Much Effort for Some Traces?系统性硬化症中的微量元素缺乏——有些微量元素太“微量”了吗?
Nutrients. 2024 Jun 27;16(13):2053. doi: 10.3390/nu16132053.
9
Systemic Sclerosis With a Normotensive Scleroderma Renal Crisis: A Diagnostic Dilemma.伴有血压正常的硬皮病肾危象的系统性硬化症:诊断难题
Cureus. 2024 Jul 9;16(7):e64167. doi: 10.7759/cureus.64167. eCollection 2024 Jul.
10
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort.厘清吸烟与系统性硬化症之间的关系:对 EUSTAR 队列的分析。
RMD Open. 2024 May 20;10(2):e004101. doi: 10.1136/rmdopen-2024-004101.
用于检测早期弥漫性皮肤系统性硬化症成人间质性肺病的肺功能测试的性能特征。
Arthritis Rheumatol. 2020 Nov;72(11):1892-1896. doi: 10.1002/art.41415. Epub 2020 Sep 22.
4
Prognostic value of cardiopulmonary exercise testing in patients with systemic sclerosis.心肺运动试验在系统性硬化症患者中的预后价值。
BMC Pulm Med. 2019 Nov 29;19(1):230. doi: 10.1186/s12890-019-1003-7.
5
Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature.系统性硬化症的生存和预后因素:一项法国多中心队列研究、系统评价和文献荟萃分析的数据。
Arthritis Res Ther. 2019 Apr 3;21(1):86. doi: 10.1186/s13075-019-1867-1.
6
Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication.硬皮病性肾危象:一种日益罕见的器官并发症的风险因素。
J Rheumatol. 2020 Feb;47(2):241-248. doi: 10.3899/jrheum.180582. Epub 2019 Apr 1.
7
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.硬皮病临床试验联盟损伤指数(SCTC-DI)的制定与验证:一种评估系统性硬化症器官损伤的新型工具。
Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30.
8
Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.系统性硬化症患者的间质性肺病短期进展可预测两个独立临床试验队列的长期生存。
Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.
9
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.肺动脉高压风险系统性硬化症患者死亡和心肺住院的风险因素:PHAROS 注册研究。
J Rheumatol. 2019 Feb;46(2):176-183. doi: 10.3899/jrheum.180018. Epub 2018 Oct 1.
10
Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study.系统性硬皮病的生存率、死亡原因和危险因素:一项大型队列研究。
Clin Rheumatol. 2018 Nov;37(11):3051-3056. doi: 10.1007/s10067-018-4291-z. Epub 2018 Sep 18.